Focus on urinary bladder cancer markers: a review

Area of Science:

• Uro-oncology
• Biomarker Discovery
• Cancer Diagnostics

Background:

• The field of bladder cancer marker discovery is rapidly evolving.
• Numerous biomarkers exist, necessitating a focused review of key diagnostic tools.
• Accurate diagnosis and staging are critical for effective bladder cancer management.

Purpose of the Study:

• To review the role of bladder cancer markers in diagnosis.
• To highlight recently studied and clinically significant bladder cancer biomarkers.
• To discuss the clinical importance of these markers in aiding diagnosis.

Main Methods:

• A literature search was conducted using MEDLINE.
• The review focuses on selected key bladder cancer markers across various categories.
• Discussion includes the clinical utility and diagnostic value of each marker.

Main Results:

• Key markers reviewed include Hematuria, FISH, FGFR3, SURVIVIN, u-PAR, TP53 mutation, HER-2/neu, TPA, NMP22, CK-19, CK-20, and CYFRA 21-1.
• The diagnostic utility and clinical significance of these markers were discussed.
• The review emphasizes the importance of specific markers in clinical practice.

Conclusions:

• Further research into recurrence and progression markers will enhance individualized bladder cancer treatment.
• Molecular staging of urological tumors is essential for selecting appropriate systemic therapies.
• Integrating basic and clinical research is vital for advancing bladder cancer diagnostics and treatment.